Literature DB >> 21062262

Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction.

Sun-Young Joo1, Kyung-Ah Cho, Yun-Jae Jung, Han-seong Kim, Seong-Yeol Park, Yong-Bock Choi, Kyung-man Hong, So-Youn Woo, Ju-Young Seoh, Kyung-Ha Ryu.   

Abstract

Cell therapy using MSCs (mesenchymal stem cells) might be effective treatment for refractory GVHD (graft-versus-host disease). However, the fate and distribution of MSCs after transplantation remains unclear. In this study, an animal model was developed to monitor the dynamic distribution of MSCs in mice with GVHD. A GVHD mouse model was established by transplanting C57BL/6 donor bone marrow cells and C57BL/6 EGFP (enhanced green fluorescent protein) splenocytes into lethally irradiated BALB/c nude recipient mice. Donor MSCs were obtained from MHC-identical C57BL/6 RFP (red fluorescent protein) mice and infused into the recipient mice on the same transplantation day. In vivo movement of the donor splenocytes (EGFP) and MSCs (RFP) were evaluated by measuring the biofluorescence (IVIS-Xenogen system). Donor splenocytes and MSCs reached the lungs first, and then the gastrointestinal tract, lymph nodes and skin, in that order; the transit time and localization site of these cells were very similar. In the recipient mouse with GVHD, the number of detectable cells declined with time, as assessed by biofluorescence imaging and confirmed by RT (real-time)-PCR. This bioimaging system might be useful for preclinical testing and the design of therapeutic strategies for monitoring the dynamic distribution of MSCs with GVHD.

Entities:  

Mesh:

Year:  2011        PMID: 21062262     DOI: 10.1042/CBI20100563

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  12 in total

1.  Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo.

Authors:  Hong-Chao Zhang; Xin-Bin Liu; Shu Huang; Xiao-Yun Bi; Heng-Xiang Wang; Li-Xian Xie; Yong-Qi Wang; Xiao-Fang Cao; Jun Lv; Feng-Jun Xiao; Yang Yang; Zi-Kuan Guo
Journal:  Stem Cells Dev       Date:  2012-09-28       Impact factor: 3.272

Review 2.  Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation.

Authors:  Minoo Battiwalla; A John Barrett
Journal:  Tissue Eng Part B Rev       Date:  2014-04-22       Impact factor: 6.389

Review 3.  Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.

Authors:  Sanaz Keshavarz Shahbaz; Amir Hossein Mansourabadi; Davood Jafari
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 4.330

4.  Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease.

Authors:  Partow Kebriaei; Simon Robinson
Journal:  Front Oncol       Date:  2011-07-04       Impact factor: 6.244

5.  Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.

Authors:  Sanaz Keshavarz Shahbaz; Amir Hossein Mansourabadi; Davood Jafari
Journal:  Clin Exp Immunol       Date:  2022-02-08       Impact factor: 5.732

6.  Quantification of Mesenchymal Stem Cell (MSC) delivery to a target site using in vivo confocal microscopy.

Authors:  Luke J Mortensen; Oren Levy; Joseph P Phillips; Tara Stratton; Brian Triana; Juan P Ruiz; Fangqi Gu; Jeffrey M Karp; Charles P Lin
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

7.  Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation.

Authors:  Minhwa Park; Yu-Hee Kim; So-Youn Woo; Hye Jin Lee; Yeonsil Yu; Han Su Kim; Yoon Shin Park; Inho Jo; Joo-Won Park; Sung-Chul Jung; Hyukjin Lee; Byeongmoon Jeong; Kyung-Ha Ryu
Journal:  Sci Rep       Date:  2015-02-27       Impact factor: 4.379

8.  Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by modulating T cell function through CCR2-CCL2 axis.

Authors:  Min Cao; Huihui Liu; Yujun Dong; Wei Liu; Zhengyu Yu; Qingya Wang; Qingyun Wang; Zeying Liang; Yuan Li; Hanyun Ren
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

Review 9.  The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation.

Authors:  Eun-Jung Kim; Nayoun Kim; Seok-Goo Cho
Journal:  Exp Mol Med       Date:  2013-01-10       Impact factor: 8.718

Review 10.  The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation.

Authors:  Ke Zhao; Qifa Liu
Journal:  J Hematol Oncol       Date:  2016-05-18       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.